Production and Characterization of Human Monoclonal Antibody Fab Fragments to Vaccinia Virus from a Phage-Display Combinatorial Library

Schmaljohn, Connie S.; Yunchang, Cui; Kerby, Stephen; Pennock, David G.; Spik, Kristin

doi:10.1006/viro.1999.9701

Cited by 29 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1D) or when challenged with other strains of vaccinia virus (data not shown). This hemin-induced cellular protection against vaccinia virus, measured as the virus titer in the infected MDM, was similar to that provided by treatment with the vaccinia-neutralizing 10F5 monoclonal antibody [14] (Fig. 1E).…”

Section: Resultssupporting

confidence: 64%

Non-coding RNAs and heme oxygenase-1 in vaccinia virus infection

Meseda

Srinivasan

Wise

et al. 2014

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Small nuclear RNAs (snRNAs) are <200 nucleotide non-coding uridylate-rich RNAs. Although the functions of many snRNAs remain undetermined, a population of snRNAs is produced during the early phase of infection of cells by vaccinia virus. In the present study, we demonstrate a direct correlation between expression of the cytoprotective enzyme heme oxygenase-1 (HO-1), suppression of selective snRNA expression, and inhibition of vaccinia virus infection of macrophages. Hemin induced HO-1 expression, completely reversed virus-induced host snRNA expression, and suppressed vaccinia virus infection. This involvement of specific virus-induced snRNAs and associated gene clusters suggests a novel HO-1-dependent host-defense pathway in poxvirus infection.

show abstract

Section: Resultssupporting

confidence: 64%

Non-coding RNAs and heme oxygenase-1 in vaccinia virus infection

Meseda

Srinivasan

Wise

et al. 2014

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

show abstract

“…Although some human anti-VACV neutralizing MAbs have been reported (40), with one exception, all of the neutralizing MAbs used to date in passive transfer studies are of rodent origin and thus require humanization to be useful. The exception, a chimpanzee/human MAb against the B5 glycoprotein (8) was derived from the bone marrow of a chimpanzee that had been vaccinated with VACV.…”

mentioning

confidence: 99%

Characterization of Chimpanzee/Human Monoclonal Antibodies to Vaccinia Virus A33 Glycoprotein and Its Variola Virus Homolog In Vitro and in a Vaccinia Virus Mouse Protection Model

Chen

Earl

Americo

et al. 2007

J Virol

View full text Add to dashboard Cite

Three distinct chimpanzee Fabs against the A33 envelope glycoprotein of vaccinia virus were isolated and converted into complete monoclonal antibodies (MAbs) with human ␥1 heavy-chain constant regions. The three MAbs (6C, 12C, and 12F) displayed high binding affinities to A33 (K d of 0.14 nM to 20 nM) and may recognize the same epitope, which was determined to be conformational and located within amino acid residues 99 to 185 at the C terminus of A33. One or more of the MAbs were shown to reduce the spread of vaccinia virus as well as variola virus (the causative agent of smallpox) in vitro and to more effectively protect mice when administered before or 2 days after intranasal challenge with virulent vaccinia virus than a previously isolated mouse anti-A33 MAb (1G10) or vaccinia virus immunoglobulin. The protective efficacy afforded by anti-A33 MAb was comparable to that of a previously isolated chimpanzee/human anti-B5 MAb. The combination of anti-A33 MAb and anti-B5 MAb did not synergize the protective efficacy. These chimpanzee/human anti-A33 MAbs may be useful in the prevention and treatment of vaccinia virus-induced complications of vaccination against smallpox and may also be effective in the immunoprophylaxis and immunotherapy of smallpox and other orthopoxvirus diseases.

show abstract

“…Phage libraries have been developed to generate the most specific antibody or antibody fragment. The generation of antibody fragments has been used for the detection of Clostridium difficile toxin B [25], Brucella melitensis [26], vaccinia virus [27] and botulinum toxin [28].…”

Section: Developments In Established Methodsmentioning

confidence: 99%

Bioshock: Biotechnology and Bioterrorism

Moorchung

Sharma

Mehta³

2009

Medical Journal Armed Forces India

View full text Add to dashboard Cite

In the recent past, the threat of a global bioterrorist attack has increased dramatically. In addition to the already existing microorganisms and techniques, the recent explosion in biotechnology has considerably added to the arsenal of the bioterrorist. Molecular technologies are now available which can be used by committed bioterrorist groups to manipulate and modify microorganisms so as to make them increasingly infectious, virulent or treatment resistant for causing maximum casualties. Infectious diseases which are likely to be used as bioweapons are Anthrax, Botulism, Plague, Smallpox and Brucella. Molecular techniques like immunoassays and nucleic acid amplification are now available to detect bioattacks. This article discusses the threat of bioterrorism. It also evaluates the molecular diagnostic methods and the future of early containment of a bioterrorist attack using molecular techniques. MJAFI 2009; 65 : 359-362

show abstract

Production and Characterization of Human Monoclonal Antibody Fab Fragments to Vaccinia Virus from a Phage-Display Combinatorial Library

Cited by 29 publications

References 32 publications

Non-coding RNAs and heme oxygenase-1 in vaccinia virus infection

Non-coding RNAs and heme oxygenase-1 in vaccinia virus infection

Characterization of Chimpanzee/Human Monoclonal Antibodies to Vaccinia Virus A33 Glycoprotein and Its Variola Virus Homolog In Vitro and in a Vaccinia Virus Mouse Protection Model

Bioshock: Biotechnology and Bioterrorism

Contact Info

Product

Resources

About